Results challenge view that high testosterone fuels prostate cancer growth ...

A personalized peptide vaccine slashed prostate-specific antigen levels by as much as 99.6% in some men with advanced prostate cancer, according to a phase II clinical trial conducted at Kurume ...

It’s important to follow guidance on prostate-specific antigen screening that maximizes benefits and minimizes potential harms such as overdiagnosis and overtreatment.

NEW YORK (Reuters Health) - Hypoxia, or reduced oxygen levels, in prostate tumors significantly predicts a poor long-term biochemical outcome, regardless of other prognostic factors, such as tumor ...

A new study led by researchers at The University of Texas MD Anderson Cancer Center found that prostate cancer patients with low testosterone levels may have a higher risk of cancer progressing to ...

After decades of overtreatment for low-risk prostate cancer and inadequate management of its more aggressive forms, patients are now more likely to receive medical care matched to level of risk, ...

A single PSA test at midlife may identify men with a low risk of prostate cancer for up to 20 years, supporting longer screening intervals. Men with a low baseline PSA level at midlife have a low risk ...

Learn the key warning signs of prostate cancer that men often overlook. Early awareness can make all the difference.

FDA approves Pylarify TruVu, a new prostate cancer PET imaging agent designed to expand access and improve detection of recurrent or metastatic disease.